IL105092A - History of 1-Phenyl-3-) Troirylalkyl (pyrido] D-2,3 [pyrimidine-H1, H) -32,4 (-Dion and-pyrido-] D-2,3 [- pyrimidine-H1, H) - 32 (-on - Google Patents

History of 1-Phenyl-3-) Troirylalkyl (pyrido] D-2,3 [pyrimidine-H1, H) -32,4 (-Dion and-pyrido-] D-2,3 [- pyrimidine-H1, H) - 32 (-on

Info

Publication number
IL105092A
IL105092A IL105092A IL10509293A IL105092A IL 105092 A IL105092 A IL 105092A IL 105092 A IL105092 A IL 105092A IL 10509293 A IL10509293 A IL 10509293A IL 105092 A IL105092 A IL 105092A
Authority
IL
Israel
Prior art keywords
pyrido
pyrimidine
formula
dione
pyridylmethyl
Prior art date
Application number
IL105092A
Other languages
English (en)
Hebrew (he)
Other versions
IL105092A0 (en
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of IL105092A0 publication Critical patent/IL105092A0/xx
Publication of IL105092A publication Critical patent/IL105092A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL105092A 1992-03-20 1993-03-18 History of 1-Phenyl-3-) Troirylalkyl (pyrido] D-2,3 [pyrimidine-H1, H) -32,4 (-Dion and-pyrido-] D-2,3 [- pyrimidine-H1, H) - 32 (-on IL105092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/855,179 US5264437A (en) 1992-03-20 1992-03-20 Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones

Publications (2)

Publication Number Publication Date
IL105092A0 IL105092A0 (en) 1993-07-08
IL105092A true IL105092A (en) 1998-06-15

Family

ID=25320543

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105092A IL105092A (en) 1992-03-20 1993-03-18 History of 1-Phenyl-3-) Troirylalkyl (pyrido] D-2,3 [pyrimidine-H1, H) -32,4 (-Dion and-pyrido-] D-2,3 [- pyrimidine-H1, H) - 32 (-on

Country Status (16)

Country Link
US (1) US5264437A (no)
EP (2) EP1770093A1 (no)
JP (1) JP3241384B2 (no)
KR (1) KR100274104B1 (no)
CN (1) CN1040327C (no)
AU (1) AU669520B2 (no)
CA (1) CA2132297C (no)
FI (1) FI106960B (no)
HU (2) HUT67552A (no)
IL (1) IL105092A (no)
MX (1) MX9301530A (no)
NO (1) NO301763B1 (no)
NZ (1) NZ251525A (no)
TW (1) TW240226B (no)
WO (1) WO1993019068A1 (no)
ZA (1) ZA931945B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
KR970705562A (ko) * 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
JPH11500110A (ja) * 1995-02-10 1999-01-06 シエーリング アクチエンゲゼルシヤフト Ｔｎｆ−抑制用製剤
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JP2000119272A (ja) * 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
JP2005507419A (ja) * 2001-11-01 2005-03-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲン合成酵素キナーゼ３ベータ阻害剤としてのアミド誘導体
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
MEP8009A (en) * 2006-09-15 2011-12-20 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
TW200835497A (en) * 2007-01-11 2008-09-01 Astrazeneca Ab Chemical compounds 636
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
EP2297106B1 (en) 2008-05-27 2014-07-16 AstraZeneca AB Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
WO2023042879A1 (ja) * 2021-09-17 2023-03-23 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性複素環誘導体およびそれらを含有する医薬組成物
CN113831491B (zh) * 2021-09-30 2023-03-24 南昌大学 一种嘧啶唑共价有机框架的制备方法及吸附应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649917B2 (no) * 1973-12-18 1981-11-25
DE2523730A1 (de) * 1974-06-12 1976-02-12 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidinonen
JPS58428B2 (ja) * 1974-07-05 1983-01-06 ヒサミツセイヤク カブシキガイシヤ シンキナ ２− オキソ −１，２，３，４− テトラヒドロピリド （ ２，３−ｄ ） ピリミジンユウドウタイノ セイゾウホウ
DE3770095D1 (de) * 1986-08-21 1991-06-20 Pfizer Chinazolindione und pyridopyrimidindione.
DE69327312T2 (de) * 1992-04-29 2000-07-13 Stanford Res Inst Int Deazaaminopterine für behandlung von entzündungen

Also Published As

Publication number Publication date
WO1993019068A1 (en) 1993-09-30
CN1078470A (zh) 1993-11-17
FI944305A (fi) 1994-09-16
NZ251525A (en) 1996-09-25
CN1040327C (zh) 1998-10-21
NO943456D0 (no) 1994-09-16
US5264437A (en) 1993-11-23
ZA931945B (en) 1994-09-18
JP3241384B2 (ja) 2001-12-25
NO301763B1 (no) 1997-12-08
MX9301530A (es) 1994-01-31
FI106960B (fi) 2001-05-15
AU3918693A (en) 1993-10-21
TW240226B (no) 1995-02-11
KR100274104B1 (ko) 2000-12-15
HUT67552A (en) 1995-04-28
CA2132297C (en) 2006-01-03
HU9402653D0 (en) 1994-11-28
KR950700909A (ko) 1995-02-20
FI944305A0 (fi) 1994-09-16
IL105092A0 (en) 1993-07-08
AU669520B2 (en) 1996-06-13
EP0631580A1 (en) 1995-01-04
NO943456L (no) 1994-09-16
JPH07504676A (ja) 1995-05-25
CA2132297A1 (en) 1993-09-30
EP1770093A1 (en) 2007-04-04
HU210873A9 (en) 1995-08-28

Similar Documents

Publication Publication Date Title
IL105092A (en) History of 1-Phenyl-3-) Troirylalkyl (pyrido] D-2,3 [pyrimidine-H1, H) -32,4 (-Dion and-pyrido-] D-2,3 [- pyrimidine-H1, H) - 32 (-on
US5455252A (en) Optionally substituted 6,8-quinolines
US5466697A (en) 8-phenyl-1,6-naphthyridin-5-ones
AU670544B2 (en) Benzo and pyrido pyridazinone and pyridazinthione compounds with PDE IV inhibiting activity
US5804588A (en) Quinoline carboxanides and their therapeutic use
US20180222891A1 (en) 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US20180228780A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
JPH07505407A (ja) インドール誘導体
CN101124229B (zh) 用于治疗炎性和过敏性障碍的新杂环化合物
US5716954A (en) Benzopyridazinone and pyridopyridazinone compounds
US5530005A (en) Method of use of 8-phenylcyclopentenoquinoline and 8-phenylcyclohexenoquinoline derivatives
JPS63159382A (ja) １−置換ナフチリジンおよびピリドピラジン誘導体
CA2159603C (en) Quinolines as type iv phosphodiesterase inhibitors
JPS62223150A (ja) １，４−ベンゾキノン誘導体
MXPA98009740A (en) Quinoline carboxamides as fnt inhibitors and as fde inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees